Elevated Plasma Fibrinogen and Diabetes Mellitus Are Associated With Lower Inhibition of Platelet Reactivity With Clopidogrel

Journal of the American College of Cardiology

Volumn 52, Issue 13, 2008, Pages 1052-1059

  Ang, Lawrence ^a   Palakodeti, Vachaspathi ^a   Khalid, Ahmer ^a   Tsimikas, Sotirios ^a   Idrees, Zaheib ^a   Tran, Phillip ^a   Clopton, Paul ^a   Zafar, Nayab ^a   Bromberg Marin, Guilherme ^a   Keramati, Shahin ^a   Mahmud, Ehtisham ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

body mass index; clopidogrel; diabetes mellitus; fibrinogen; platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIET THERAPY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; TREATMENT RESPONSE;

AGED; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; TICLOPIDINE;

EID: 51449118219     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.05.054     Document Type: Article

References (32)

1. Braunwald E., Antman E.M., Beasley J.W., et al. American College of Cardiology; American Heart Association. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40 (2002) 1366-1374
2. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49 (2007) 2312-2317
3. Malinin A., Pokov A., Spergling M., et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: the VERIfy Thrombosis risk Assessment (VERITAS) study. Thromb Res 119 (2007) 277-284
4. Serebruany V.L., Steinhubl S.R., Berger P.B., Malinin A.I., Bhatt D.L., and Topol E.J. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005) 246-251
5. Van Werkum J.W., van der Stelt C.A.K., Seesing T.H., Hackeng C.M., and ten Berg J.M. A head-to-head comparison between the VerifyNow® P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 4 (2006) 2516-2518
6. Michelson A.D., Frelinger III A.L., and Furman M.I. Current options in platelet function testing. Am J Cardiol 98 (2006) S4-S10
7. Mahmud E., and Ang L. Monitoring antiplatelet therapy during peripheral vascular and coronary interventions. Tech Vasc Interv Radiol 9 (2006) 56-63
8. Steinhubl S.R. Platelets. In: Michelson A.D. (Ed). The VerifyNow System. 2nd edition (2006), Elsevier/Academic Press, San Diego, CA 509-518
9. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
10. Gurbel P.A., and Tantry U.S. Clopidogrel resistance?. Thromb Res 120 (2007) 311-321
11. Nguyen T.A., Diodati J.G., and Chantal P. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45 (2005) 1157-1164
12. Carr M.E. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 15 (2001) 44-54
13. Murray J.J., Nowak J., Oates J.A., et al. Platelet-vessel wall interactions in individuals who smoke cigarettes. Adv Exp Med Biol 273 (1990) 189-198
14. Badimon J.J., Badimon L., Turitto V.T., et al. Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. In vivo study in the rabbit model. Arterioscler Thromb Vasc Biol 11 (1991) 395-402
15. Surya I.I., and Akkerman J. The influence of lipoproteins on blood platelets. Am Heart J 125 (1993) 272-275
16. A polymorphism, fibrinogen, and platelet aggregability. The Framingham Heart study. Circulation 104 (2001) 140-144
17. Furman M.I., Benoit S.E., Barnard M.R., et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 31 (1998) 352-358
18. Mahmud E., Cavendish J.J., Tsimikas S., et al. Elevated fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention. J Am Coll Cardiol 49 (2007) 2163-2171
19. Han J., Lim C.W., Watanabe N., et al. Reconstructing and deconstructing agonist-induced activation of integrin αIIbβ3. Curr Biol 16 (2006) 1796-1806
20. Malinin A., Pokov A., Swain L., Kotob M., and Serebruany V. Validation of a VerifyNow P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 28 (2006) 315-322
21. Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 23 (1997) 349-356
22. Malanin A.I., Spergling M., Muhlestein B., Steinhubl S., and Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 15 (2004) 295-301
23. Lowe G.D.O. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 3 (2005) 1618-1627
24. Kristiansen O.P., and Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes 54 (2005) S114-S124
25. Woodward M., Lowe G.D.O., Francis L.M.A., Rumley A., Cobbe S.M., and CADET Study Investigators. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost 2 (2004) 1934-1940
26. Angiolillo D.J., Bernardo E., Ramirez C., et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48 (2006) 298-304
27. Ferriera I.A., Mocking A.I., Feijge M.A., et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 26 (2006) 417-422
28. Winocour P.D., Watala C., Perry D.W., and Kinlough-Rathbone R.L. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost 68 (1992) 577-582
29. Kishimoto T., Akira S., Narazaki M., and Taga T. Interleukin-6 family of cytokines and gp130. Blood 86 (1995) 1243-1254
30. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?. J Invasive Cardiol 16 (2004) 169-174
31. Kelly R.V., Hsu A., Topol E., and Steinhubl S. The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention. J Invasive Cardiol 18 (2006) 115-119
32. Saw J., Brennan D.M., Steinhubl S.R., et al., CHARISMA Investigators. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 50 (2007) 291-295